The fluconazole era: Management of hematogenously disseminated candidiasis in the nonneutropenic patient

Pharmacotherapy

Volumn 17, Issue 3, 1997, Pages 538-548

  Kramer, Katherine M ^a,b   Skaar, Debra J ^a   Ackerman, Bruce H ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; REVIEW; UNITED STATES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CATHETERIZATION; CRITICAL ILLNESS; CROSS INFECTION; FLUCONAZOLE; FUNGEMIA; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031009718     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia, the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
3. Komshian SV, Uwayday AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;2:379-90.
4. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
5. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
6. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy 1994;40:92-8.
7. Berenguer J, Fernandez-Baca V, Sanchez R, Bouza E. In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections. Eur J Clin Microbiol Infect Dis 1995;14:362-5.
8. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
9. Gaines JD, Remington JS. Disseminated candidiasis in the surgical patient. Surgery 1972;72:730-6.
10. Solomkin JS, Flohr AB, Quie PG, et al. The role of Candida in intraperitoneal infections. Surgery 1980;83:524-30.
11. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.
12. Anaissie E, Solomkin JS. Fungal infection. In: Wilmore DW, Cheung LY, Harkin AH, Holcroft JW, Meakins JL, eds. Scientific American surgery. New York: Scientific American, 1996:1-19.
13. Solomkin JS. Pathogenesis and management of Candida infection syndromes in nonneutropenic patients. New Horiz 1993;1:202-13.
14. Parker JC, McCloskey JJ, Knauer KA. Pathobiologic features of human candidiasis: a common deep mycosis of the brain, heart, and kidney in the altered host. Am J Clin Pathol 1976;65:991-1000.
15. Meunier F. Candidiasis. Eur J Clin Microbiol Infect Dis 1989;8:438-47.
16. Edwards JE, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis 1992;14(suppl 1):S106-13.
17. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1-8.
18. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10-27.
19. Finley RW, Cleary JD, Goolsby J, Chapman SW. Fluconazole penetration into the human prostate. Antimicrob Agents Chemother 1995;39:553-5.
20. Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988;28:363-6.
21. Roerig-Pfizer. Diflucan (fluconazole) package insert. New York, NY; 1994.
22. Gearhart M. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994;28:1177-81.
23. Bennett JE. Antimicrobial agents. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The pharmacologic basis of therapeutics. New York: Pergamon Press, 1990:1165-81.
24. van Etten EWM, van de Rhee NE, van Kampen KM, Bakker-Woudenberg IAJM. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother 1991;35:2275-81.
25. Pharmacia. Amphocin (amphotericin B) package insert. Columbus, OH; 1994.
26. Atkinson AJ, Bennet JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13:271-6.
27. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Cromelin DJA. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1992:23(4):279-91.
28. Christiansen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985;152:1037-43.
29. Morgan D, Ching M, Raymond K, et al. Elimination of amphotericin in impaired renal function. Clin Pharmacol Ther 1983;34:248-53.
30. McEvoy GK, Litvak K, Welsh OH, eds. AHFS 96 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1996:73.
31. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis 1987;156:784-9.
32. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
33. Gardner ML, Godley PJ, Wasan SM. Sodium loading treatment for amphotericin B-induced nephrotoxicity. Ann Pharmacother 1990;24:940-5.
34. Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969;46:154-62.
35. Sawaya BP, Welhprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991;87:2097-2107.
36. Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988;21:665-72.
37. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12(suppl):239S-47.
38. Kujath P, Lerch K. Secondary mycosis in surgery: treatment with fluconazole. Infection 1989;17:111-17.
39. Nolla-Salas J, Leon C, Torres-Rodriquez JM, Martin E, Sitges-Serra A. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 1992;14:952-4.
40. Milatovic D, Voss A. Efficacy of fluconazole in the treatment of systemic fungal infections. Eur J Clin Microbiol Infect Dis 1992;11:395-402.
41. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993;26:133-46.
42. Kujath P, Lerch K, Kochendorfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376-82.
43. Rex JH, Bennett JE, Sugar AM. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
44. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995;155:2429-35.